A Study of LY3537031 in Overweight, Obese, and Healthy Participants

Condition(s) studied

Investigational drug(s) / intervention(s)

LY3537031: Administered SC

Placebo: Administered SC

Study summary

This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants.

Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 49 weeks excluding a screening period.

Eligibility

Primary outcome measure(s)

• Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration — Baseline to Study Completion (Up to 56 Weeks)
  A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module

Trial sites (5)

More Eli Lilly and Company trials in the USA

Other trials for the same condition